Search for content, post, videos

Recipharm makes €40m investment


Recipharm will invest €40m over the next three years to ensure state of-the-art solutions for serialisation processes.
The move by the company comes as the announcement of the EU Falsified Medicines Directive (EUFMD) Safety Features Delegated Regulation is released. This means that the serialisation of
licensed drug products will be a legal requirement for companies in the EU from early 2019. Recipharm already provides serialised products in markets including Turkey, Korea and China. A
newly established, global steering committee will now also work closely with clients in Europe to ensure they plan and implement changes that comply with pending regulatory requirements for drug serialisation.
The CDMO’s company-wide serialisation project is being led by Staffan Widengren, Director Corporate Projects at Recipharm. He said: “Having worked with many clients in Asia on track and
traceability, we know the complications and challenges of serialising a product from start to finish. The process can be complex and time consuming, particularly if the right tools and expertise are
not in place, so we need to move this issue up the agenda for firms in Europe. We know that several pharmaceutical companies are behind in their preparations, mainly because the changes seem so far away. In reality, these organisations must look ahead and face this issue head on as changes take a long time to implement in a complex supply chain. As a company, we are aiming to be as proactive as possible with the introduction of serialisation in order to support and advise our clients, create a clear strategy and prepare them for inevitable changes. If companies are underprepared, the new requirements have the potential to significantly impact their product supply. As a result, we expect to see increased demand for specialist outsourced services as the deadline looms ever closer.”

The industry-wide serialisation, aggregation and verification directive is expected to improve traceability of drugs, help in the fight against counterfeit products entering the supply chain and
ultimately improve patient safety. However, the implementation of required changes to the 2D barcodes on all saleable drug items is set to require significant investment from the pharmaceutical industry. Recipharm serves 250+ customers and expects 85% of its production to require serialisation. The CDMO will also be ready for US serialisation from November 2017 in-line with the US Drug Supply Chain Security Act (DSCSA).

Source: Recipharm